COPENHAGEN, Denmark, Oct. 9, 2025 – (cGxP.wire) – Adcendo ApS, a biotechnology company pioneering first- and best-in-class antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADCE-D01, its lead clinical-stage candidate for the treatment of soft tissue sarcoma (STS). The designation underscores ADCE-D01’s potential to fill a critical therapeutic gap in a group of malignancies with limited effective treatment options.
Science Significance
ADCE-D01 represents a breakthrough in next-generation ADC design. It targets urokinase plasminogen activator receptor-associated protein (uPARAP), an endocytic receptor overexpressed in mesenchymal cancers, including multiple soft tissue sarcoma subtypes. The therapy employs a Topoisomerase I inhibitor payload (P1021), providing potent tumor-cell killing through precise internalization and DNA damage. In preclinical models, ADCE-D01 demonstrated robust anti-tumor activity and a favorable safety profile, with no evidence of target-specific toxicity in non-human primates. This suggests a potentially wider therapeutic window compared with existing sarcoma therapies. Adcendo’s uPARAP-targeting approach opens a new scientific avenue for mesenchymal tumor treatment, positioning the company at the forefront of precision oncology.
Regulatory Significance
Fast Track Designation by the FDA marks a pivotal regulatory milestone for Adcendo and validates ADCE-D01’s therapeutic promise. The designation provides enhanced access to FDA guidance, allowing more frequent meetings and data exchanges aimed at accelerating clinical development and regulatory review. As part of the FDA’s expedited programs, Fast Track status also allows eligibility for Accelerated Approval, Priority Review, and Rolling Review, which can significantly reduce time to market. These regulatory tools will enable Adcendo to advance ADCE-D01 toward potential commercialization more efficiently, reinforcing the FDA’s commitment to supporting innovative therapies for rare and aggressive cancers. Dr. Victoria Marsh, Global Head of Regulatory Affairs at Adcendo, emphasized, “With this Fast Track designation, ADCE-D01 will now benefit from more frequent interactions with the FDA. Increased engagement will help expedite development and bring this therapy to patients sooner.”
Business Significance
Advertisement
From a business perspective, this milestone solidifies Adcendo’s position among the most promising ADC developers globally. Fast Track designation often serves as a signal of clinical and scientific credibility, attracting strategic investment, partnerships, and licensing interest from major biopharma players seeking ADC innovation. Adcendo’s dual operations in Copenhagen and Boston provide it access to both European and U.S. capital and clinical ecosystems. With a leadership team of ADC veterans who have previously driven multiple therapies to approval, Adcendo is strategically positioned to capitalize on the rising demand for next-generation ADCs targeting novel tumor antigens. CEO Michael Pehl noted, “This recognition of our uPARAP-targeting drug candidate represents another meaningful milestone for Adcendo. Our approach has the potential to transform the sarcoma treatment landscape and overcome limitations seen with current options.”
Patients’ Significance
For patients with soft tissue sarcoma, this announcement carries deep clinical hope. Sarcomas are rare and highly heterogeneous malignancies, often resistant to conventional chemotherapy. With ADCE-D01 now under Fast Track status, patients could gain earlier access to a targeted therapy that specifically addresses the biology of their disease. The ADCElerate1 clinical trial—a Phase I/II multicenter, open-label dose escalation and expansion study—is already underway in the United States and Europe. The trial is assessing safety, tolerability, pharmacokinetics, and preliminary efficacy of ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. By enabling earlier regulatory dialogue and review, the Fast Track pathway may shorten the time between promising clinical data and real-world patient availability, accelerating relief for a community with few effective treatments.
Policy Significance
At the policy level, the FDA’s action aligns with broader global initiatives to accelerate rare cancer therapy approvals. Programs such as Fast Track, Breakthrough Therapy, and Orphan Drug Designations illustrate an evolving regulatory philosophy emphasizing speed, precision, and patient access. For oncology stakeholders, this designation signals continued regulatory prioritization of ADCs—a modality increasingly viewed as a key pillar of precision medicine policy frameworks in the U.S. and Europe. It reinforces the commitment to reduce barriers to innovation while ensuring rigorous safety oversight.
Transaction Highlights
Adcendo ApS has achieved a major regulatory milestone with the U.S. Food and Drug Administration granting Fast Track Designation to ADCE-D01, the company’s first-in-class antibody-drug conjugate (ADC) designed for the treatment of soft tissue sarcoma (STS). ADCE-D01 specifically targets the urokinase plasminogen activator receptor-associated protein (uPARAP)—a receptor highly overexpressed in mesenchymal cancers—and is conjugated to a Topoisomerase I inhibitor payload (P1021). The candidate has demonstrated potent anti-tumor activity in preclinical models and a favorable safety profile in toxicology studies, showing no target-specific toxicity. The therapy is currently being evaluated in the ADCElerate1 Phase I/II clinical trial, an open-label, multicenter study assessing safety, tolerability, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS. The study is actively enrolling in both the United States and Europe under ClinicalTrials.gov identifier NCT06797999 and EUCT 2024-516900-41-00. Through this designation, Adcendo gains enhanced access to FDA interactions, enabling more frequent guidance and the potential for Accelerated Approval, Priority Review, and Rolling Review—mechanisms that can significantly shorten the timeline from development to patient access. The achievement reinforces Adcendo’s leadership in the next wave of antibody-drug conjugate innovation and highlights the company’s commitment to transforming the treatment landscape for sarcoma patients with urgent unmet medical needs.
Source: Adcendo Press Release
